SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19 th

- Data Shows Additional Evidence of CA4P Activity - - Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs)

SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that shares of its common stock will be eligible for

- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients achieved a complete remission - SOUTH SAN FRANCISCO, Calif. , Dec.

SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for

SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the special meeting of stockholders scheduled for

- Patients with Measurable Disease Showed Significantly Improved Progression-Free Survival - - Progression-Free Survival Improved by 6.2 Months for Patients with Larger Tumors - SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc .

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced the appointment of two new members to its board of

SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.

SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced a collaboration under which sites affiliated with US